Compare Ascendis Pharma A/S (ASND) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Garmin Ltd. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Garmin Ltd. trades at $309.51 (market cap $60.39B). The key difference: Garmin Ltd. is far larger — about 3.6× Ascendis Pharma A/S's market cap, and Garmin Ltd. pays a 1.34% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GRMN | |
|---|---|---|
Market Cap | $16.78B | $60.39B |
Sector | Health | Technology |
52-Week High | $277.18 | $313.16 |
52-Week Low | $189.74 | $187.10 |
Enterprise Value | $17.15B | $57.91B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
Garmin (GRMN) trades at $310.89, up 2.96% today and near its all-time high, with a bullish technical trend supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.81 versus $2.30 expected, and raised full-year guidance. Revenue growth is robust, driven by the fitness segment, with 2025 revenue at $7.25 billion and net income margin of 24.47%.
Outlook is positive due to sustained demand for wearables and upward revisions, but risks include rich valuations (P/E of 32.08) and potential growth deceleration. Analyst consensus is cautious with 74% hold ratings, though the price target of $318.67 suggests modest upside. Investors should weigh strong fundamentals against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
